文献速递MDS 与骨髓增殖性肿瘤白血病

SETD2缺陷通过S100a9加速NHD13小鼠MDS相关白血病发生并预测MDS不良预后

SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
PubMed 文献 · Blood · 2020-01-01

本研究探讨SETD2在骨髓增生异常综合征(MDS)中的作用。MDS患者中SETD2低表达与生存期缩短相关,且地西他滨可提高CD34+骨髓细胞中SETD2水平。在NHD13转基因小鼠中敲除Setd2可加速MDS向急性髓系白血病(AML)转化,机制涉及S100a9及其下游Ikba和Jnk。

要点

  • MDS患者中SETD2低表达与生存期缩短相关
  • NHD13小鼠中Setd2缺失加速MDS向AML转化
  • S100a9是Setd2靶基因,重组S100a9可减弱Setd2缺陷效应

核心结论

  • SETD2缺陷预测MDS不良预后并促进MDS向AML转化,提供潜在治疗靶点。

研究设计与样本

  • 研究在NUP98-HOXD13(NHD13)转基因小鼠中敲除Setd2,该小鼠表型模拟人类MDS。
  • 分析MDS患者CD34+骨髓细胞中SETD2表达及其与生存的关系。
  • 采用RNA-seq和染色质免疫沉淀测序(ChIP-seq)分析Setd2靶基因。

主要发现

  • MDS患者中SETD2低表达与生存期缩短相关,且地西他滨可提高CD34+骨髓细胞中SETD2水平。
  • NHD13小鼠中Setd2缺失加速MDS向AML转化,增强造血干祖细胞(HSPC)自我更新能力,增加对称性自我更新分裂,减少分化和细胞死亡。
  • Setd2缺失上调NHD13+ HSPC中造血干细胞信号并下调髓系分化通路。
  • S100a9是Setd2靶基因,添加重组S100a9可减弱Setd2缺陷对NHD13+ HSPC的影响;下调S100a9导致其下游靶点Ikba和Jnk减少。
  • 通过表观遗传修饰药物提高H3K36me3水平可抑制MDS相关白血病细胞生长。

临床怎么用

  • SETD2低表达可作为MDS预后不良的预测指标。
  • 地西他滨可能提高MDS患者CD34+细胞中SETD2水平。
  • 表观遗传修饰药物提高H3K36me3或靶向S100a9可能成为MDS相关急性白血病的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SETD2, the histone H3 lysine 36 methyltransferase, previously identified by us, plays an important role in the pathogenesis of hematologic malignancies, but its role in myelodysplastic syndromes (MDSs) has been unclear. In this study, low expression of SETD2 correlated with shortened survival in patients with MDS, and the SETD2 levels in CD34+ bone marrow cells of those patients were increased by decitabine. We knocked out Setd2 in NUP98-HOXD13 (NHD13) transgenic mice, which phenocopies human MDS, and found that loss of Setd2 accelerated the transformation of MDS into acute myeloid leukemia (AML). Loss of Setd2 enhanced the ability of NHD13+ hematopoietic stem and progenitor cells (HSPCs) to self-renew, with increased symmetric self-renewal division and decreased differentiation and cell death. The growth of MDS-associated leukemia cells was inhibited though increasing the H3K36me3 level by using epigenetic modifying drugs. Furthermore, Setd2 deficiency upregulated hematopoietic stem cell signaling and downregulated myeloid differentiation pathways in the NHD13+ HSPCs. Our RNA-seq and chromatin immunoprecipitation-seq analysis indicated that S100a9, the S100 calcium-binding protein, is a target gene of Setd2 and that the addition of recombinant S100a9 weakens the effect of Setd2 deficiency in the NHD13+ HSPCs. In contrast, downregulation of S100a9 leads to decreases of its downstream targets, including Ikba and Jnk, which influence the self-renewal and differentiation of HSPCs. Therefore, our results demonstrated that SETD2 deficiency predicts poor prognosis in MDS and promotes the transformation of MDS into AML, which provides a potential therapeutic target for MDS-associated acute leukemia.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chen BY, Song J, Hu CL, et al. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS. Blood. 2020. PMID: 32202636. doi:10.1182/blood.2019001963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。